NSCLC Resource Center - Quiz 2

Which of the following TKI is approved for treating both ALK and ROS1 rearrangements in patients with NSCLC?
Osimertinib
Crizotinib
Ceritinib
Lorlatinib
Which of the following TKI is approved for first-line treatment in EGFR mutation-positive advanced NSCLC as well as for individuals who harbor a T790M resistant mutation?
Gefitinib
Savolitinib
Osimertinib
Cabozantinib
True/False. EMLA-Anaplastic Lymphoma Kinase (ALK) rearrangements are due to deletions in the DNA of the tumor causing proliferation of the cancer cells.
True
False
ROS1 and ALK rearrangements are more common in which patients?
Younger patients
Older patients
Smokers
None of the above
0
{"name":"NSCLC Resource Center - Quiz 2", "url":"https://www.quiz-maker.com/QQH27WUBI","txt":"Which of the following TKI is approved for treating both ALK and ROS1 rearrangements in patients with NSCLC?, Which of the following TKI is approved for first-line treatment in EGFR mutation-positive advanced NSCLC as well as for individuals who harbor a T790M resistant mutation?, True\/False. EMLA-Anaplastic Lymphoma Kinase (ALK) rearrangements are due to deletions in the DNA of the tumor causing proliferation of the cancer cells.","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys